U3-1784
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Hepatocellular Cancer (HCC)
Trial Timeline
Feb 29, 2016 → Feb 28, 2017
NCT ID
NCT02690350About U3-1784
U3-1784 is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT02690350. Target conditions include Advanced Solid Tumors, Hepatocellular Cancer (HCC).
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02690350 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumors